Daiichi Sankyo Launches Enrollment for Clinical Testing in Neuropathic Pain, Neuralgia and Fibromyalgia

Daiichi Sankyo Launches Enrollment for Clinical Testing in Neuropathic Pain, Neuralgia and Fibromyalgia
Daiichi Sankyo Company Ltd., the second largest pharmaceutical company in Japan, has just opened patient enrollment for a large-scale, international clinical research program, designed to determine the safety and efficacy profile of pipeline drug mirogabalin (DS-5565), a first-in-class selective alpha-2 delta ligand. The drug will be tested on peripheral neuropathic pain, postherpetic neuralgia, and pain secondary to fibromyalgia. The newly-launched Phase III clinical research program includes 3 studies; two of which will be conducted all across Asia:
  1. REDUCER - An Asian, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of DS-5565 in patients with diabetiC pEripheral neuRopa
    Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *